| __timestamp | Amneal Pharmaceuticals, Inc. | Rhythm Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 84615000 | 1213000 |
| Thursday, January 1, 2015 | 109679000 | 3425000 |
| Friday, January 1, 2016 | 118757000 | 6311000 |
| Sunday, January 1, 2017 | 109046000 | 9518000 |
| Monday, January 1, 2018 | 230435000 | 28080000 |
| Tuesday, January 1, 2019 | 289598000 | 36550000 |
| Wednesday, January 1, 2020 | 326727000 | 46125000 |
| Friday, January 1, 2021 | 365504000 | 68486000 |
| Saturday, January 1, 2022 | 399700000 | 92032000 |
| Sunday, January 1, 2023 | 429675000 | 117532000 |
Infusing magic into the data realm
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Amneal Pharmaceuticals, Inc. and Rhythm Pharmaceuticals, Inc. have taken different paths in this regard over the past decade. From 2014 to 2023, Amneal's SG&A expenses have surged by over 400%, peaking at approximately $430 million in 2023. In contrast, Rhythm Pharmaceuticals started with a modest $1.2 million in 2014, growing to $117 million by 2023, marking an exponential increase of nearly 9,600%.
While Amneal's expenses have grown steadily, Rhythm's rapid increase reflects its aggressive expansion strategy. However, Amneal's larger scale and consistent growth suggest a more stable approach to managing costs. This comparison highlights the diverse strategies companies employ to balance growth and cost management in the pharmaceutical industry.
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Rhythm Pharmaceuticals, Inc.
argenx SE and Rhythm Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Cost Management Insights: SG&A Expenses for Neurocrine Biosciences, Inc. and Amneal Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Rhythm Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Incyte Corporation and Amneal Pharmaceuticals, Inc.
Selling, General, and Administrative Costs: Catalent, Inc. vs Rhythm Pharmaceuticals, Inc.
Operational Costs Compared: SG&A Analysis of Grifols, S.A. and Rhythm Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: Amneal Pharmaceuticals, Inc. vs ImmunityBio, Inc.
Selling, General, and Administrative Costs: CymaBay Therapeutics, Inc. vs Rhythm Pharmaceuticals, Inc.
Comparing SG&A Expenses: Rhythm Pharmaceuticals, Inc. vs Perrigo Company plc Trends and Insights
Rhythm Pharmaceuticals, Inc. or Amphastar Pharmaceuticals, Inc.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Rhythm Pharmaceuticals, Inc. or Xencor, Inc.